Article (Scientific journals)
Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus.
Scheen, André
2014In Clinical Pharmacokinetics
Peer Reviewed verified by ORBi
 

Files


Full Text
TXT SGLT2 DDIs CLEAN Revised version SCHEEN for Clinical Pharmacokinetics.pdf
Author preprint (150.56 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Glucose-lowering therapy – Pharmacokinetics – –; Type 2 diabetes mellitus; Dapagliflozin; Drug-drug interaction; Canagliflozin; Empagliflozin; Pharmacokinetics
Abstract :
[en] Inhibitors of sodium-glucose cotransporters type 2 (SGLT2) reduce hyperglycaemia by decreasing renal glucose threshold and thereby increasing urinary glucose excretion. They are proposed as a novel approach for the management of type 2 diabetes mellitus. They have proven their efficacy in reducing glycated haemoglobin, without inducing hypoglycaemia, as monotherapy or in combination with various other glucose-lowering agents, with the add-on value of promoting some weight loss and lowering arterial blood pressure. As they may be used concomitantly with many other drugs, we review the potential drug-drug interactions (DDIs) regarding the three leaders in the class (dapagliglozin, canagliflozin and empagliflozin). Most of the available studies were performed in healthy volunteers and have assessed the pharmacokinetic interferences with a single administration of the SGLT2 inhibitor. The exposure [assessed by peak plasma concentrations (C max) and area under the concentration-time curve (AUC)] to each SGLT2 inhibitor tested was not significantly influenced by the concomitant administration of other glucose-lowering agents or cardiovascular agents commonly used in patients with type 2 diabetes. Reciprocally, these medications did not influence the pharmacokinetic parameters of dapagliflozin, canagliflozin or empagliflozin. Some modest changes were not considered as clinically relevant. However, drugs that could specifically interfere with the metabolic pathways of SGLT2 inhibitors [rifampicin, inhibitors or inducers of uridine diphosphate-glucuronosyltransferase (UGT)] may result in significant changes in the exposure of SGLT2 inhibitors, as shown for dapagliflozin and canagliflozin. Potential DDIs in patients with type 2 diabetes receiving chronic treatment with an SGLT2 inhibitor deserve further attention, especially in individuals treated with several medications or in more fragile patients with hepatic and/or renal impairment.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
English
Title :
Drug-Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus.
Publication date :
2014
Journal title :
Clinical Pharmacokinetics
ISSN :
0312-5963
eISSN :
1179-1926
Publisher :
Adis International, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 13 March 2014

Statistics


Number of views
1144 (2 by ULiège)
Number of downloads
5427 (1 by ULiège)

Scopus citations®
 
63
Scopus citations®
without self-citations
54
OpenCitations
 
53
OpenAlex citations
 
69

publications
0
supporting
0
mentioning
0
contrasting
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Bibliography


Similar publications



Sorry the service is unavailable at the moment. Please try again later.
Contact ORBi